Details of the Drug Combination

General Information of Drug Combination (ID: DCNJ129)

Drug Combination Name
Pramipexole Linagliptin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Pramipexole   DMNMW9R Linagliptin   DMWFJTR
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 24.82
Bliss Independence Score: 24.82
Loewe Additivity Score: 39.67
LHighest Single Agent (HSA) Score: 39.68

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pramipexole
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Approved [2]
Pramipexole Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Modulator [7]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [7]
------------------------------------------------------------------------------------
Pramipexole Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [8]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Indication(s) of Linagliptin
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [3]
Type 2 diabetes 5A11 Approved [4]
Type-2 diabetes 5A11 Approved [5]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
Linagliptin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [10]
HUMAN dipeptidyl peptidase 4 (DPP-4) TTF928K DPP4_HUMAN Inhibitor [11]
------------------------------------------------------------------------------------
Linagliptin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 953).
3 Linagliptin FDA Label
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6318).
6 ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7.
9 OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011 Feb;12(1):79-82.
10 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
11 DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26.
12 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.